CD80 anticorps (AA 251-321)

N° du produit ABIN678683

Détail du produit anti-CD80 anticorps

Antigène: CD80

Épitope: AA 251-321

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CD80 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Réactivité croisée: Humain, Souris, Rat

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from rat CD80

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Références pour anticorps anti-CD80 (ABIN678683)

Han, Wang, Qin, Xia, Wu: "LPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4." dans: Journal of experimental & clinical cancer research : CR, Vol. 36, Issue 1, pp. 83, (2018) (PubMed).

da Silva Junior, Mesquita-Ferrari, França, Andreo, Bussadori, Fernandes: "Modulating effect of low intensity pulsed ultrasound on the phenotype of inflammatory cells." dans: Biomedicine & pharmacotherapy, Vol. 96, pp. 1147-1153, (2017) (PubMed).

Chen, Li, Zhao, Liang, Ma, Li, Zhu: "Prevention of ultraviolet radiation‑induced immunosuppression by sunscreen in Candida albicans‑induced delayed‑type hypersensitivity." dans: Molecular medicine reports, Vol. 14, Issue 1, pp. 202-8, (2016) (PubMed).

Ju, Xing, Yang, Zheng, Jia, Zhang, Ren: "An effective cytokine adjuvant vaccine induces autologous T-cell response against colon cancer in an animal model." dans: BMC immunology, Vol. 17, Issue 1, pp. 31, (2016) (PubMed).

Wang, Hu, Wang, Gu, Gao, Cao, Zheng: "5-Aminolevulinic acid-mediated sonodynamic therapy reverses macrophage and dendritic cell passivity in murine melanoma xenografts." dans: Ultrasound in medicine & biology, Vol. 40, Issue 9, pp. 2125-33, (2014) (PubMed).

Détails sur CD80

Antigène: CD80

Autre désignation: CD80 (CD80 Produits)

Sujet:

Synonyms: B7-1, Activation B7 1 antigen, Activation B71 antigen, B lymphocyte activation antigen B7, B7, BB1, CD 80, CD28 antigen ligand 1 B7 1 antigen, CD28 antigen ligand 1 B71 antigen, CD28LG, CD28LG1, CD80 antigen, CD80 antigen precursor,CD80 Molecule, Costimulatory factor CD80, CTLA 4 counter receptor B7.1, CTLA-4 counter-receptor B7.1, LAB 7, LAB7, T lymphocyte activation antigen CD80, CD80_MOUSE.

Background: CD80 is a member of the Ig superfamily and serves as the ligand for two T cell molecules, CD28 and CTLA4. Interactions between CD28 and CD80 on activated B cells result in enhanced T cell activation. CD80 is rapidly induced on the surface of in vitro activated B cells, Epstein Barr Virus (EBV) transformed B cell lines, Burkitts lymphoma cell lines, freshly isolated follicular B lymphoma cells, T cells, and monocytes. It is also expressed at high levels in dendritic cells. It reacts weakly with a small proportion of non activated normal B cells and with HTLV1 infected T cells. CD80 does not react with peripheral monocytes, resting and activated normal T cells, T cell lines and T cell clones, nor with myelomonocytic cell lines.

ID gène: 25408

UniProt: G3V671

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints